drugset
Drugs / CMV/EBV specific T-cell
last change Mar 2017 re-read 3 minutes ago

CMV/EBV specific T-cell

Cell therapy

Developed for
disease related to hematopoietic stem cell transplant
Investigated by
BayImmuNet Bavarian Immunotherapy Network · Charite University, Berlin, Germany · German Research Foundation · Johannes Gutenberg University Mainz · Ludwig-Maximilians - University of Munich · University Hospital Augsburg
+2 more · University of Erlangen-Nürnberg Medical School · University of Regensburg

Trials 1

today NCT02227641 · Ph 1/2
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT02227641 Oct 2014 → Oct 2016 disease related to hematopoietic stem cell transplant University of Erlangen-Nürnberg Medical School Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CMV/EBV specific T-cell ClinicalTrials.gov intervention name — accepted as the source's own label NCT02227641 ↗
Action Restore “This study therefore aims at reconstituting the T-cell compartment” NCT02227641 ↗
Modality Cell therapy “adoptive immunotherapy with allogeneic CMV/EBV Specific, Peptide Stimulated T-cells (CD3+)” NCT02227641 ↗